Warden-Rothman, 2015 - Google Patents
The development, use, and optimization of sortase-tag expressed protein ligationWarden-Rothman, 2015
View PDF- Document ID
- 964318357098200554
- Author
- Warden-Rothman R
- Publication year
External Links
Snippet
Molecular imaging is an emerging field that seeks to combine the mechanistic detail of biochemical assays with the the broad phenotypic data obtained from non-invasive medical imaging. A cornerstone of molecular imaging is the ability to chemically attach a contrast …
- 102000004169 proteins and genes 0 title abstract description 263
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
- A61K47/48769—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form
- A61K47/48853—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form the form being a particulate, powder, adsorbate, bead, sphere
- A61K47/48861—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form the form being a particulate, powder, adsorbate, bead, sphere the form being an inorganic particle, e.g. a ceramic particle, silica particle, ferrite, synsorb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
- A61K47/48369—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying part being an antibody, an immunoglobulin, or a fragment thereof, e.g. a Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Sioud | Phage display libraries: from binders to targeted drug delivery and human therapeutics | |
Löfblom et al. | Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications | |
Ståhl et al. | Affibody molecules in biotechnological and medical applications | |
Heo et al. | An aptamer-antibody complex (oligobody) as a novel delivery platform for targeted cancer therapies | |
US10156559B2 (en) | Lipocalin fusion partners | |
Miller et al. | T cell receptor-like recognition of tumor in vivo by synthetic antibody fragment | |
US10738115B2 (en) | Humanized antibodies transmigrating the blood-brain barrier and uses thereof | |
Sánchez-Martín et al. | The multicompartmental p32/gClqR as a new target for antibody-based tumor targeting strategies | |
US20170267755A1 (en) | Isolated anti-mesothelin antibodies, conjugates and uses thereof | |
CN114106099A (en) | Substrates and other cleavable moieties for proteolytic enzymes and U-type plasminogen activators and methods of use thereof | |
US10605810B2 (en) | Pincers comprising antibody and aptamer conjugated via a linker which binds to the same target material and use thereof | |
JP2014515600A5 (en) | ||
Pung et al. | Generation of peptides using phage display technology for cancer diagnosis and molecular imaging | |
CN116444666A (en) | Preparation method and application of CDH17 specific diagnosis and treatment integrated molecular imaging probe | |
CN115461354B (en) | Tandem repeat cancer targeting peptides for molecular conjugation or modification and their use in cancer theranostics | |
Choi et al. | Complexation of drug and hapten-conjugated aptamer with universal hapten antibody for pancreatic cancer treatment | |
WO2022148491A1 (en) | Assembled protein element and use thereof | |
JP6969014B2 (en) | How to bond antibody and bioactive substance | |
CN115925951A (en) | Preparation method and application of CD70 specific diagnosis and treatment integrated molecular image probe | |
US8507207B2 (en) | Recombinant nucleotide sequence, cell or vector containing the same and method for using cell containing the same to encode anti-polyethylene glycol monoclonal antibodies | |
Pozdniakova et al. | Using ELP repeats as a scaffold for de novo construction of gadolinium-binding domains within multifunctional recombinant proteins for targeted delivery of gadolinium to tumour cells | |
Case et al. | Engineered charge redistribution of Gp2 proteins through guided diversity for improved PET imaging of epidermal growth factor receptor | |
Case et al. | Evaluation of affibody charge modification identified by synthetic consensus design in molecular PET imaging of epidermal growth factor receptor | |
Warden-Rothman | The development, use, and optimization of sortase-tag expressed protein ligation | |
oh Jung et al. | A new fluorescence/PET probe for targeting intracellular human telomerase reverse transcriptase (hTERT) using Tat peptide-conjugated IgM |